BioMarin's gene therapy pipeline has had setbacks, including a three-year delay in US approval of Roctavian and stalled development of PKU gene therapy BMN 307 as the Food and Drug Administration ...
Pfizer will end global development of its bleeding disorder gene therapy, Beqvez, the Nikkei reported on Thursday.
FDA approves an expanded access program that would offer patients an alternative to Merck’s bladder cancer medication.
VIXERAN biostimulant enables farmers to optimize nitrogen fertilizer use and transition to more sustainable on-farm practices ...
A total of 118 recommendations based on expert consensus were published regarding the treatment of hidradenitis suppurativa ...
Challenging powerhouse Pfizer, BridgeBio's launch of Attruby is off to a 'great start,' analyst says
An intriguing battle is brewing in the market to treat patients with transthyretin amyloid cardiomyopathy (ATTR-CM). | BridgeBio reported that 1,028 unique prescriptions have been written by 516 ...
GlobalData on MSN15h
FDA authorises ImmunityBio’s BCG alternative to treat bladder cancerImmunityBio has gained US Food and Drug Administration (FDA) authorisation for an expanded access programme to supply an ...
“Partnering with Genesis Therapeutics presents a unique opportunity to leverage their AI technologies to accelerate the ...
Why did “ Biotech is in a dark place ” resonate with so many of you? Because it’s true! Collectively, we’re all frustrated ...
Acid reducing medicines from the group of proton pump inhibitors (PPIs) are best-selling drugs that prevent and alleviate ...
Vincent Gaynor remembers, almost to the minute, when he realized his part in birthing the breakthrough gene therapy Zolgensma ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback